---
title: "STAAR Surgical Company Stock 12‑Month Price Target Raised to $23.56, Implies 20% Downside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286375263.md"
description: "STAAR Surgical Company's stock price target has been raised to $23.56 from $21.11, indicating a potential downside of about 20%. The forecasts from 9 analysts range from $16 to $33 per share. The consensus rating remains a 'Hold' with 2 Buy ratings, 9 Hold ratings, and no Sell ratings among 11 analysts covering the stock."
datetime: "2026-05-14T07:20:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286375263.md)
  - [en](https://longbridge.com/en/news/286375263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286375263.md)
---

# STAAR Surgical Company Stock 12‑Month Price Target Raised to $23.56, Implies 20% Downside

-   According to estimates from 9 analysts, STAAR Surgical Company stock's average price target has risen from $21.11 to $23.56, with forecasts ranging from $16 to $33 per share
-   Based on the May 13 closing price, the updated target implies approximately 20% potential downside
-   Consensus rating remains at “Hold” across 11 covering analysts, with 2 Buys, 9 Holds and 0 Sells

Explore more price target data and ratings for STAAR Surgical Company on the , and track all previous and future analyst recommendations for STAAR Surgical Company in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [STAA.US](https://longbridge.com/en/quote/STAA.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Earnings To Watch: STAAR Surgical (STAA) Reports Q1 Results Tomorrow](https://longbridge.com/en/news/286027616.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Earnings Beat: Odfjell Drilling Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286515920.md)